Rhythm Pharmaceuticals, Inc. RYTM
98.66
0.35
0.36%
as of 25 Sep
- Market cap
- $6.8B
- P/E
- 0.0×
Follow RYTM
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(247.13%) | (251.14%) | (293.04%) | (461.65%) | |
| (45.44%) | (46.29%) | (50.14%) | (51.91%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(50.60%) | (55.77%) | (63.37%) | (69.36%) | |
Average Days of Receivables |
69.16 | 50.17 | 57.47 | 61.47 | |
Free Cash Flow per Share |
(2.26) | (2.42) | (1.76) | (1.54) | |
Free Cash Flow |
(149.63) | (157.13) | (119.51) | (105.35) | |
Capital Expenditures |
(40.50) | (41.45) | — | — | |
Piotroski F-Score |
5.00 | 4.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(15.33%) | (17.55%) | (20.67%) | (19.22%) | |
Accounts Receivable Turnover |
6.66 | 8.51 | 8.35 | 7.21 | |
Accounts Payable Turnover |
2.00 | 1.48 | 1.90 | 1.64 | |
Inventory Turnover |
1.03 | 0.88 | 0.96 | 1.07 | |
Average Days of Payables |
269.29 | 261.17 | 195.17 | 223.59 | |
Days of Inventory on Hand |
436.73 | 482.24 | 454.66 | 422.10 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.01 | |
Research and Development Expense of Revenue |
95.49% | 88.19% | 79.24% | 72.20% | |
Selling, General and Administrative Expense of Revenue |
100.72% | 102.73% | 101.05% | 100.43% | |
Share Based Compensation of Revenue |
33.33% | 35.21% | 35.48% | 36.36% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.55 | 0.57 | 0.58 | 0.50 | |
Depreciation/Fixed assets |
6.11 | 1.21 | 1.13 | 10.48 | |
Capex/Depreciation |
(27.95) | (30.98) | 0.00 | 0.00 | |
Revenue per Share |
2.63 | 2.92 | 3.19 | 3.50 | |
Operating CF per Share |
(1.65) | (1.78) | (1.76) | (1.54) | |
Capex per Share |
(0.61) | (0.64) | 0.00 | 0.00 | |
Capex to Sales |
0.23 | 0.22 | 0.00 | 0.00 | |
Net Profit Margin |
(113.43%) | (106.41%) | (95.71%) | (87.62%) |
Columns are period end dates